Insider Buying: GlaxoSmithKline plc (GSK) Insider Acquires 10 Shares of Stock
GlaxoSmithKline plc (LON:GSK) insider Dominic Redfern purchased 10 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The shares were bought at an average cost of GBX 1,343 ($18.55) per share, with a total value of £134.30 ($185.55).
Dominic Redfern also recently made the following trade(s):
- On Wednesday, January 10th, Dominic Redfern purchased 10 shares of GlaxoSmithKline stock. The shares were bought at an average cost of GBX 1,333 ($18.42) per share, with a total value of £133.30 ($184.17).
GlaxoSmithKline plc (LON:GSK) opened at GBX 1,316.40 ($18.19) on Wednesday. GlaxoSmithKline plc has a 52-week low of GBX 1,235.20 ($17.07) and a 52-week high of GBX 1,724.50 ($23.83). The firm has a market capitalization of $65,280.00 and a price-to-earnings ratio of 2,483.77.
Several equities research analysts recently weighed in on GSK shares. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,760 ($24.32) price target on shares of GlaxoSmithKline in a report on Wednesday, December 13th. UBS Group set a GBX 1,550 ($21.41) target price on GlaxoSmithKline and gave the company a “buy” rating in a report on Wednesday, December 13th. Deutsche Bank raised their target price on GlaxoSmithKline from GBX 1,380 ($19.07) to GBX 1,440 ($19.89) and gave the company a “hold” rating in a report on Thursday, January 11th. JPMorgan Chase & Co. set a GBX 1,340 ($18.51) target price on GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday, January 4th. Finally, Bank of America set a GBX 1,450 ($20.03) target price on GlaxoSmithKline and gave the company a “neutral” rating in a report on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and an average price target of GBX 1,538.18 ($21.25).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.